Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

NCT02168829 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1284

Enrollment

OTHER

Sponsor class

Conditions

Atrial Fibrillation
Stroke

Interventions

DRUG: Rivaroxaban
DRUG: Acetylsalicylic acid

Sponsor

Ottawa Heart Institute Research Corporation

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]